Navigation Links
FUISZ Announces Advances in Devices and Solid Dosage Form
Date:7/1/2010

MIAMI, July 1 /PRNewswire/ -- FUISZ today announced two medical technology advances.

First, FUISZ announced that it has received a notice of issuance from the United States Patent and Trademark Office for patent claims that cover a direct connection between prescribing physicians and blood analysis devices.  The invention allows for the health care provider to set the parameters of allowable analyte levels for each patient and enables simple notifications for any variance out of a pre-determined range. Joseph Fuisz, managing member of FUISZ stated, "These patent claims represents a quantum leap in the use of portable blood analyzers to provide a higher level of care for patients while reducing burdens on health care providers. We are in discussions with the blood analyzer industry for the licensing of this technology."

FUISZ also announced that it has filed a new patent in the field of solid oral Bioactive dosage forms. This novel system works to enhance or retard drug absorption.  It is particularly well suited to buccal, sublinqual and other forms of mucosal delivery including nano particles.  Joseph Fuisz commented, "This innovation can be readily adapted for use with existing products to improve control of drug absorption.  It will be particularly well received in the opiate market where controlling relative absorption of opiates and agonists is so critical.  This technology draws upon our deep knowledge of quick dissolve dosage forms and applies that knowledge in a broad manner to all solid dosage forms."

FUISZ is a family owned company. Fuisz principals Richard Fuisz, M.D. and Joseph Fuisz, Esq. are named inventors on or owners of hundreds of patents and patent applications. These patents span several fields: drug delivery, quick dissolve dosage forms including quick dissolve tablets, thin films, slow dissolve sheets, conventional oral dosage units, opiate abuse resistance, women's health, electronic mail, e-commerce, and tobacco. The company is based in Miami, Florida. www.fuisz.com.


'/>"/>
SOURCE FUISZ
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
2. Fuisz Pharma Announces Novel Anti Abuse System for Opiates
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , February 9, 2016 ... QIA) gab heute den Abschluss eines Kooperationsvertrags ... Förderung umfassender Lösungen in den Bereichen Next-Generation-Sequencing ... QGEN ; Frankfurt Prime Standard: QIA) ... 10x Genomics für die Entwicklung und Förderung ...
(Date:2/9/2016)... 9, 2016 Mast Therapeutics, Inc. (NYSE ... sickle cell disease and heart failure, today announced that it ... purchase common stock in an underwritten public offering.  The offering ... be no assurance as to whether or when the offering ... terms of the offering.   --> ...
(Date:2/9/2016)... 9, 2016 Hearing protection devices refer to ... transmitted to the inner ear. Hearing protection devices include ... devices are recommended for users exposed to noise levels ... to HPD that are inserted in the ear canal ... to provide more natural sound perception with the help ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... ... Establishment Labs, a global breast implant and medical technology company, is pleased ... , “We are honored to welcome David to our Board of Directors. ... Quiros, CEO of Establishment Labs. "David’s knowledge and experience will be invaluable to our ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... service to expand access to affordable hearing aids , increase industry transparency, ... individuals in the United States. , “For the average consumer, the hearing aid ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... sealing company , is proud to announce that many of their franchises have ... customer service. The hard surface restoration franchises received customer recognition through positive reviews ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Federal Laboratory ... federallabs.org . The site houses a wealth of federal resources that businesses can ... process called technology transfer (T2). As a network of over 300 federal laboratories, ...
(Date:2/8/2016)... Los Angeles, CA (PRWEB) , ... February 08, 2016 , ... A man who has ... CEO of Freedom Laser Therapy , was determined to find solutions to his problems ... story of Inventors Digest is ready to introduce his breakthrough inventions to the ...
Breaking Medicine News(10 mins):